SURGX^®

Last Line of Defense Against Surgical Site Infections

Biofilm can form at the incision site in less than one hour and lead to a surgical site infection. These infections can have serious prolonged health implications and lengthen a patient’s hospital stay.

SURGX Sterile Antimicrobial Gel is designed to help reduce surgical site and post-surgical infections by destroying planktonic and biofilm based bacteria within the gel. The proprietary XBIO formulation conforms to the post-operative wound to provide proven broad-spectrum efficacy and prevent surface attachment of free-floating bacteria, with sustained effectiveness for up to 5 days.¹³

Product Features

– Up to 7 log reduction within 2 minutes¹⁴
– No known antimicrobial resistance
– Broad spectrum efficacy¹⁴
– Sustained efficacy up to 5 days¹³
– Non-toxic*
* when used as per the IFU

Mechanism of Action

SURGX uses patented XBIO Technology to attack biofilm structures, breaking the strong metallic bonds that hold the EPS together. This exposes the bacteria within the biofilm and makes them more vulnerable to attack and eradication. Bacteria that are enveloped within the biofilm disruption technology then experience cell lysis through a high osmolarity imbalance across the bacterial cell membrane and wall. XBIO Technology’s broad-spectrum efficacy helps defend from biofilm reformation.

Learn more

Product Efficacy
Competitive Comparison
Clinical and Scientific Evidence
Compatibility
Product Q&A

Product Efficacy¹⁴

Studies show SURGX provides broad-spectrum efficacy and multi-log microorganism reduction.

Competitive Comparison¹³

SURGX demonstrates up to 5-day efficacy in preventing MRSA bacterial growth.

Clinical and Scientific Evidence

Stevenson, P. Myntti, M. (2020). SurgX® in the role of SSSI prevention: Clinical Observations Supporting the Integration of Antibiofilm Strategy into Surgical Incision Management. Jacksonville, FL: Next Science.

Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti M, Hakaim
A. Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach. Wounds. Epub 2018.

Wolcott R. Disrupting the biofilm matrix improves wound healing outcomes. Journal of wound care. 2015 Aug;24(8):366-71.

Miller KG, Tran PL, Haley CL, et al. Next science wound gel technology, a novel agent that inhibits biofilm development by gram-positive and gram-negative wound pathogens. Antimicrob Agents Chemother. 2014;58(6):3060–3072.

Compatibility^15,16

*It is not recommended to be used with silver dressing as SURGX will deactivate the silver, however, the combination does not pose a risk to the patient.

All trademarks and registered trademarks are the property of their respective owners.